SLNO Q4 2024 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$59M

Net Income

-$56M

EPS (Diluted)

$-1.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$331M

Total Liabilities

$86M

Stockholders' Equity

$245M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$59M	-$14M	-325.0%
Net Income	-$56M	-$11M	-395.6%